Clinical trials: Phosphorus Metabolism
Chronic Kidney Disease, Dialysis
Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
The primary objective of this study is to demonstrate the long-term safety and tolerability of MCI-196 in the subjects with stage V chronic kidney disease on dialysis with hyperphosphatemia.
- Conditions
- Chronic Kidney Disease, Dialysis, Hyperphosphatemia
- Trial name
- NCT00772382
- Testing
- MCI-196
- Where
- 21 sites in United States, Canada
- Volunteers
- 116 people
- Sponsor
- Tanabe Pharma Corporation
Hyperphosphatemia
Dose Finding Study to Treat High Phosphate Levels in the Blood.
Randomized. double blind, placebo controlled, parallel arms dose finding study with a 4 weeks treatment period
- Trial name
- NCT02081534
- Testing
- AZD1722
- Where
- 41 sites in United States, Poland and 2 more
- Volunteers
- 162 people
- Sponsor
- Ardelyx
X-linked Hypophosphatemia
Dental Implants in Patients With X-linked Hypophosphatemia
X-linked hypophosphatemia (XLH) is a rare genetic skeletal disease where increased phosphate wasting in the kidney leads to hypophosphatemia and prevents normal mineralization of bone and dentin, with osteomalacia as a principal…
- Trial name
- IMPLANTS-XLH (NCT03879915)
- Testing
- Dental Implant placement
- Where
- France
- Volunteers
- 36 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
End Stage Renal Disease, Hyperphosphatemia
Phosphate Kinetic Modeling
Cardiovascular disease is a major cause of death in hemodialysis (HD) patients and is associated with widespread vascular calcification.
- Trial name
- PKM (NCT01003223)
- Testing
- Computer algorithm management of hyperphosphatemia
- Where
- United States
- Volunteers
- 190 people
- Sponsor
- Fresenius Medical Care North America
Chronic Kidney Disease, Hyperphosphatemia
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients Not on Dialysis
Approximately 207 hyperphosphatemic CKD patients not on dialysis will be entered into this study at approximately 50 sites within approximately 9 European countries.
- Trial name
- ASPIRE (NCT00833768)
- Testing
- Sevelamer carbonate
- Where
- 36 sites in Austria, France and 7 more
- Volunteers
- 5 people
- Sponsor
- Genzyme, a Sanofi Company
Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia
Low-Phosphate Diet and Fibroblast Growth Factor-23 Level
The aims of the study are to evaluate the effect of low-phosphate diet on FGF23 level and to determine the optimal amount of dietary phosphate restriction in hemodialysis patients.
- Conditions
- Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia, Dietary Intervention, Elevated Fibroblast Growth Factor-23
- Trial name
- NCT03367338
- Testing
- Low-phosphate diet
- Where
- Taiwan
- Volunteers
- 35 people
- Sponsor
- Wan-Chuan Tsai
Hyperphosphataemia
Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease
The main purpose of this study is to see whether PT20 can help people with a high level of phosphate in their blood (called Hyperphosphatemia) that are being treated with dialysis for kidney disease.
- Trial name
- NCT02151643
- Testing
- PT20
- Volunteers
- 153 people
- Sponsor
- Phosphate Therapeutics
Spinal Muscular Atrophy, Fragile X Syndrome
Early Check: Expanded Screening in Newborns
Early Check provides voluntary screening of newborns for a selected panel of conditions. The study has three main objectives: 1) develop and implement an approach to identify affected infants, 2) address the impact on infants and…
- Conditions
- Spinal Muscular Atrophy, Fragile X Syndrome, Fragile X - Premutation, Duchenne Muscular Dystrophy
- Trial name
- NCT03655223
- Testing
- Confirmatory Testing
- Where
- United States
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- RTI International
Hyperphosphatemia, End Stage Renal Disease
A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
The study is designed to evaluate the ability of tenapanor alone or in combination with sevelamer to achieve serum phosphorus concentration (sP) within the population reference range (sP >2.5 and ≤4.5 mg/dL) in patients with…
- Trial name
- NORMALIZE (NCT03988920)
- Testing
- Tenapanor, Sevelamer Carbonate
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Ardelyx
X-linked Hypophosphatemia
Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
The primary objective of this study is to establish the effect of KRN23 treatment on improvement in XLH-associated osteomalacia as determined by osteoid volume (osteoid volume/bone volume, OV/BV).
- Trial name
- NCT02537431
- Testing
- burosumab
- Where
- 14 sites in United States, Canada and 4 more
- Volunteers
- 14 people
- Sponsor
- Kyowa Kirin, Inc.
X-linked Hypophosphatemia
Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)
The objectives of the study are to: Identify a dose and dosing regimen of burosumab, based on safety and pharmacodynamic (PD) effect, in pediatric XLH participants Establish the safety profile of burosumab for the treatment of…
- Trial name
- NCT02163577
- Testing
- burosumab
- Where
- 9 sites in United States, France and 2 more
- Volunteers
- 52 people
- Sponsor
- Kyowa Kirin, Inc.
Chronic Kidney Disease
Diurnal Variation of Uremic Solutes in Peritoneal Dialysis
Study on the daytime variation of uremic retention solutes and markers of bone-mineral metabolism in patients with end-stage kidney disease treated with peritoneal dialysis
- Trial name
- NCT01093456
- Where
- Belgium
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
End-Stage Renal Disease
Fosrenol for Enhancing Dietary Protein Intake in Hypoalbuminemic Dialysis Patients (FrEDI) Study
Protein-energy wasting, as reflected by a serum albumin <4.0 g/dL, is very common in maintenance hemodialysis (MHD) patients and associated with poor clinical outcomes including high death rates.
- Trial name
- FrEDI (NCT01116947)
- Testing
- Meals during hemodialysis accompanied by lanthanum carbonate to control phosphorus
- Volunteers
- 108 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose…
- Conditions
- Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension
- Trial name
- POPS or POP02 (NCT04278404)
- Testing
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Where
- 52 sites in United States, Canada
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Duke University
Hyperphosphatemia, End Stage Renal Disease on Dialysis
Effectiveness of The Phosphate Mobile App on Serum Phosphorus in Adult Hemodialysis Patients With Hyperphosphatemia
This multi-centred randomized, open label-controlled trial consists of hemodialysis (HD) patients identified with hyperphosphatemia (>1.78mmol/L).
- Trial name
- NCT04789876
- Testing
- Phosphate mobile app, One-off dietary counselling with a phosphate booklet
- Where
- 3 sites in Malaysia
- Volunteers
- 74 people
- Sponsor
- Taylor's University
Hemodialysis, Hyperphosphatemia
Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients
The study is designed to compare sevelamer vs. calcium-based phosphate binder in hemodialysis patients to achieve full-scale of medical care, including reduction of atherosclerotic risk factors, reduction of vascular access…
- Conditions
- Hemodialysis, Hyperphosphatemia, Cardiovascular Events
- Trial name
- NCT01755078
- Testing
- Sevelamer HCl, Calcium-based phosphate binder
- Volunteers
- 166 people
- Sponsor
- Chugai Pharma Taiwan
X-linked Hypophosphatemia, Hypophosphatemic Rickets
X-linked Hypophosphatemia Disease Monitoring Program
The objectives of this observational study are to characterize XLH disease presentation and progression and to assess long-term effectiveness and safety of burosumab.
- Trial name
- NCT03651505
- Testing
- No intervention
- Where
- 38 sites in United States, Argentina and 4 more
- Volunteers
- 782 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
X-linked Hypophosphatemia (XLH)
Retrospective and Prospective Disease Progression and Quality of Life in XLH
There is limited empirical data documenting disease progression and impact on quality of life for patients with X-linked hypophosphatemia (XLH).
- Trial name
- NCT04049877
- Testing
- None - Observational study
- Where
- United Kingdom
- Volunteers
- 11 people
- Sponsor
- Medialis Ltd.
Chronic Kidney Disease, Dialysis
A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia
This is a phase III multi-centre study in two periods: the first period is a phosphate binder and lipid lowering drugs washout for 8 weeks, the second period is a double-blind, randomised, parallel group, fixed dose, for 12 weeks.
- Conditions
- Chronic Kidney Disease, Dialysis, Hyperphosphatemia, Dyslipidemia
- Trial name
- NCT00542386
- Testing
- MCI-196
- Where
- 73 sites in Hungary, Italy and 6 more
- Volunteers
- 642 people
- Sponsor
- Tanabe Pharma Corporation
Phosphorus Metabolism
Studying Phosphorus Metabolism
Phosphorus and phosphate irons play critical roles in bone structure and essential cellular functions. The purpose of this study is to learn more about the factors and hormones that regulate phosphorus in the body by collecting…
- Trial name
- NCT00066183
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)